Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results [Yahoo! Finance]
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates [Yahoo! Finance]
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results [Yahoo! Finance]